Anti-Human CD273 (PDCD1LG2) (Clone CPTC-PDCD1LG2-1) – Purified No Carrier Protein

Synthetic peptide ATLLEEQLPLGK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0105A-3A4-H1/K1 activity is directed against human PDCD1LG2 peptide sequence ATLLEEQLPLGK.

CPTC-PDCD1LG2-1

PDCD1LG2, also known as PD-L2, is a costimulatory member of the B7 family that functions as a negative regulator of immune response¹. PDCD1LG2 is a type I transmembrane glycoprotein composed of IgC and IgV-type extracellular domains² that acts as a ligand of programmed death gene 1 (PD-1)³. When bound to PD-1, PDCD1LG2 boosts T cell tolerance, inhibits T cell activation and proliferation, increases the conversion of T helper cells into Foxp3+ Treg cells, and prevents cytolysis of T cells in cancers. Abnormal upregulation of PDCD1LG2 suppresses the immune system and can lead to cancer growth³, whereas reduced expression can lead to allergic diseases such as airway inflammation and asthma².

EB0105A-3A4-H1/K1 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from residues 73-84 of human PDCD1LG2, ATLLEEQLPLGK⁴. EB0105A- 3A4-H1/K1 does not detect PDCD1LG2 by immunohistochemistry, immunofluorescence, or reverse phase protein array⁵. EB0105A-3A4-H1/K1 can be used in Western blotting analysis to detect PDCD1LG2 in buffy coat and NCI H226 cell lysates or as an isolated recombinant protein. However, PDCD1LG2 is not detectable or has inconsistent results in Western blots of HeLa, Jurkat, A549, and MCF7 cell lysates when probed with EB0105A-3A4-H1/K1.

PDCD1LG2 is expressed mainly on antigen-presenting cells, including myeloid dendritic cells and macrophages, in non-hematopoietic tissues as well as on certain T helper cell subsets and cytotoxic T cells. Abnormally elevated PDCD1LG2 expression is detected in gastric cancer, triple-negative breast cancer, and renal cell carcinoma.

PDCD1 (PD-1)

1 Greenwald RJ, Latchman YE, Sharpe AH. Curr Opin Immunol. 14(3):391-396. 2002.
2 Singh AK, Stock P, Akbari O. Allergy. 66(2):155-162. 2011.
3 Bolandi N, Derakhshani A, Hemmat N, et al. Int J Mol Sci. 22(19):10719. 2021.
4 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
5 https://antibodies.cancer.gov/detail/CPTC-PDCD1LG2-1